NCT02678884 Head and Neck Squamous Cell Carcinoma (HNSCC)PET-CT Pilot Study
| NCT ID | NCT02678884 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Health Network, Toronto |
| Condition | Head and Neck Squamous Cell Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2014-10 |
| Primary Completion | 2028-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2014-10 with a primary completion date of 2028-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to see how useful the information provided from Positron Emission Tomography (PET) scans can be in the actual planning and delivery of radiation treatment to patients who have head and neck cancers. Patients participating in this study, will have (in addition to their routine tests) a PET scan before and during their radiation treatment. Following the intervention, patients will be followed as per standard practice.
Eligibility Criteria
Inclusion Criteria: * Non-nasopharynx head and neck mucosal squamous cell carcinoma * Radiologically evident gross disease * Radiotherapy alone for curative intent * Age equal to or more than 18 years old * To be eligible for the second study PET-CT scan: FDG avid tumour (or minimum SUV of 2.5) on the first study PET-CT scan Exclusion Criteria: * Nasopharynx cancer * H\&N SCC skin * Distant metastases (already known or if found on baseline CT-thorax) * Prior malignancy within the last 5 years (exclude non-H\&N SCC, BCC skin) * Prior chemotherapy within the last 5 years or concurrent chemotherapy/EGFR inhibitors * Prior head and neck radiotherapy * Inability to lie supine for study duration * Pregnancy * Inability to provide informed consent
Contact & Investigator
John J Kim, MD
PRINCIPAL INVESTIGATOR
The Princess Margaret Cancer Foundation
Frequently Asked Questions
Who can join the NCT02678884 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Head and Neck Squamous Cell Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02678884 currently recruiting?
Yes, NCT02678884 is actively recruiting participants. Contact the research team at John.kim@rmp.uhn.on.ca for enrollment information.
Where is the NCT02678884 trial being conducted?
This trial is being conducted at Toronto, Canada.
Who is sponsoring the NCT02678884 clinical trial?
NCT02678884 is sponsored by University Health Network, Toronto. The principal investigator is John J Kim, MD at The Princess Margaret Cancer Foundation. The trial plans to enroll 20 participants.